February 3, Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

Size: px
Start display at page:

Download "February 3, Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852"

Transcription

1 February 3, 2014 Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD ATTN: Leslie Kux, Assistant Commissioner for Policy Ref: [Docket No. FDA 2013 D 1213]; Draft Guidance for Industry: Use of Donor Screening Tests to Test Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) for Infection with Treponema pallidum (Syphilis); 78 Federal Register 214; November 5, Dear Assistant Commissioner Kux: On behalf of the 85 U.S. member eye bank organizations, the Eye Bank Association of America [hereinafter referred to as the EBAA or the Association ] appreciates the opportunity to comment on the Food and Drug Administration s Draft Guidance for Industry that recommends the use of FDAlicensed, approved or cleared donor screening tests for testing donors of HCT/Ps for infection with Treponema pallidum (Syphilis). Our U.S. member organizations provide close to 100% of all corneal tissue used for transplantation in the U.S. All EBAA eye bank members are 501(c) (3) organizations whose mission is to procure and provide donated human eye tissue for sight restoring transplantation procedures. The Association strives to ensure the superior quality of banked human eye tissue through the adoption and implementation of stringent medical standards, which are scientifically based, and specific to ocular tissue. EBAA Background The EBAA is the world s oldest transplantation association, established in 1961 by the American Academy of Ophthalmology (AAO). The EBAA first established medical standards and an accreditation program for inspection of eye banking organizations in 1980, and certification of technicians followed in the late 1980s. The Association s standards and procedures have been used as a model for adaptation by other organizations in the United States, and other countries. They are reviewed and revised twice a year by a board of renowned corneal surgeons and certified technicians with expertise and extensive experience in eye banking and then formally considered by the AAO, which has endorsed them each year since The EBAA standards representing best practices in eye banking, are based on science specific to ocular tissue, and enjoy widespread recognition and acceptance. The Medical Advisory Board TH STREET NW, SUITE 1010 WASHINGTON DC RESTORESIGHT.ORG

2 is responsible for promulgating EBAA medical standards, and a U.S. Food and Drug Administration (FDA) representative sits on the board. The EBAA Accreditation Board, also established in 1980, conducts inspections of eye bank members on a regular three-year cycle or more often, as necessary. Eye banks which are accredited by the EBAA, follow EBAA medical standards, and employ EBAA procedures which closely parallel and often exceed those of the FDA Good Tissue Practice regulations. Recommendations The eye banking and corneal transplant community expects that any guidelines or regulations are consistent, reasonable and evidence-based. We have read and researched the draft guidance and have some concerns with the proposed requirement to utilize only FDA-licensed, approved, or cleared donor treponemal screening tests. Based on the comments and supporting rationales that we make in response to the draft guidance, we offer the following recommendations: Stay the publication of the final guidance until research demonstrates that treponema-specific antibody tests for the diagnosis of syphilis in donors of ocular tissue and other HCT/Ps is proven as scientifically warranted. Continue to allow FDA-cleared diagnostic serological tests for evidence of infection with T. pallidum for use as HCT/P donor screening tests. Perform parallel studies to determine if the traditional RPR screening test or the treponemaspecific screening test is likely to result in more false-positive results in a donor population with a low prevalence of syphilis. The FDA and Health Resources and Services Administration (HRSA) outline appropriate policy consideration for shared organ and tissue donors. The EBAA offers these comments in the spirit of cooperation and collegiality, and we look forward to working with the FDA and our other transplant partners to ensure the safety of corneas and other tissue provided for transplant. Based on our current recommendations, the EBAA cannot support the FDA s recommendation to test all HCT/P donors using appropriate FDA-licensed, approved, or cleared donor screening tests for T. pallidum. We take this position for the following reasons: 1) Use of treponema-specific donor screening tests may identify a higher number of patients with falsely reactive results than traditional non-treponema diagnostic tests and cannot differentiate between active disease and previous infection. 2) The Centers for Disease Control and Prevention (CDC) continues to recommend traditional screening using a nontreponemal test followed by testing of reactive sera with a treponemal test.

3 3) Because parallel studies have not been done, it is unclear if the traditional RPR screening test or the treponema-specific screening test is likely to result in more false-positive results in a HCT/P donor population. 4) FDA did not coordinate its proposal for testing requirements with HRSA, OPTN, and UNOS or consider the policy implications between organ and tissue donation and transplantation. 5) There is no evidence in the literature, either experimental or clinical, to suggest the transmission of syphilis via corneal transplantation. FDA-cleared donor screening tests for T. pallidum may identify a higher number of patients with falsely reactive results than traditional nontreponemal assays, leading to the loss of corneal donors. For years, the traditional algorithm used for the diagnosis of syphilis has called for screening with a nontreponemal assay, either the venereal disease research laboratory (VDRL) test or, more commonly, the RPR test that detects anticardiolipin antibodies. Nontreponemal tests are highly sensitive, but since these antibodies are not specific for syphilis, they may be falsely positive in circumstances such as autoimmune disease, IV drug use, pregnancy, acute viral infections, or recent immunizations. Therefore, a positive reactive nontreponemal assay (RPR or VDRL screen) must be confirmed with an assay that detects antibodies produced against T. pallidum. The FDA-cleared confirmatory test for syphilis is the fluorescent treponemal antibody absorption (FTA ABS) test. This allows for screening with a relatively inexpensive test and increased the positive predictive value (PPV) of a reactive result in the treponemal test to greater than 99%. 1 Recently, treponema-specific assays have been developed and have been cleared by the FDA as donor screening tests for T. pallidum. Some clinical laboratories and blood banks have begun to screen samples using treponemal enzyme immunoassays (EIA). This strategy will identify both persons with previous treatment and persons with untreated or incompletely treated syphilis. False-positive results can occur, particularly among populations with a low prevalence of syphilis. Of the FDA-cleared donor screening tests for syphilis, the CAPTIA TM Syphilis (T. pallidum)-g enzyme immunoassay (EIA) is most often available by commercial laboratories who provide cadaveric panels for donor testing. Unfortunately, not all commercial laboratories utilized by eye banks currently offer this test. One of the four FDA-cleared screening tests for syphilis, the ASI TPHA test is no longer available in the United States. The use of treponemal immunoassays to screen for syphilis eliminates biological false positives due to the presence of anticardiolipin antibodies from other diseases. A number of studies have shown that immunoassays have fewer false positives than nontreponemal assays. The sensitivity and specificity of the CAPTIA Syphilis-G EIA compared to standard syphilis tests were reported by Hooper and colleagues to be 100% and 99.9%, respectively, and by Reisner et al to be 100% and 99.8%, respectively. 2,3 Head-tohead comparisons showed specificities of 98% to 99% for immunoassays and consistently slightly lower specificities of 98% to 99% for RPR. 4

4 Excellent specificity notwithstanding, any test will have a poor positive predictive value when performed on populations with extremely low disease prevalence. Treponemal immunoassays do not distinguish between remote, treated infection and current, active infection. Because the CAPTIA only detects IgG antibody, a reactive CAPTIA test would rule-out any potential HCT/P donor that has been previously treated for syphilis. Furthermore, treponemal antibody tests suffer from cross-reactivity with other spirochete infections and non-syphilis Treponemal infections. For this reason, reverse algorithm guidelines recommend that all specimens positive by a treponemal immunoassay also be tested by a standard nontreponemal assay (i.e., RPR) with titer to diagnose active disease and monitor response to treatment. If the nontreponemal test is negative, then a different treponemal test should be performed to confirm the results of the initial test. If a second treponemal test is positive, persons with a history of previous treatment will require no further management unless sexual history suggests likelihood of re-exposure. Those without a history of treatment for syphilis should be offered treatment. Unless history or physical examination suggests a recent infection, previously untreated persons should be treated for late latent syphilis. In a direct comparison of reverse and traditional algorithms, Binnicker et al. reported a higher falsereactivity rate by reverse screening. 5 However, all false-reactive IgG results were negative by RPR and TPPA and the overall results would have been interpreted as negative at the completion of the testing algorithm. These false-reactive IgG results would unnecessarily eliminate potential tissue donors. A significant advantage of immunoassays is that they can be automated, significantly reducing labor and increasing sample throughput compared to other syphilis tests. While this may be useful for highvolume laboratories and screening blood donors, traditional screening is more appropriate for lowvolume clinical laboratories and eye banks. Nontreponemal assays (such as RPR) are relatively easy to perform, inexpensive, provides a more rapid screening method when low numbers of samples are tested, and do not require expensive instrumentation. Because the results are quantitative, they can be used to follow response to therapy and to detect reinfections. The EBAA requests that FDA continue to allow HCT/P establishments to utilize FDA-cleared nontreponemal diagnostic assays, which provide sufficient evidence of active, clinical disease and allow for additional confirmatory testing with treponemal tests to differentiate between true- and falsepositives. The Centers for Disease Control and Prevention (CDC) recommends screening with a nontreponemal test. CDC recommends syphilis serologic screening with a nontreponemal test, such as the rapid plasma reagin (RPR) or Venereal Disease Research Laboratory (VDRL) test, to identify persons with possible untreated infection; this screening is followed by confirmation using one of several treponemal tests. 6

5 This recommendation is based on years of experience with the traditional testing algorithm, as well as a number of studies suggesting that the results of RPR screening may show a higher degree of correlation with disease activity than the reverse testing algorithm. This is due to the fact that treponemal tests (e.g., EIA) are not able to distinguish between active disease and past, successfully treated, syphilis. In contrast, nontreponemal tests, such as RPR, generally become negative following treatment and therefore, can be used to monitor a patient s response to therapy. Nontreponemal test titers usually correlate with disease activity, and the results are reported quantitatively. CDC continues to recommend traditional screening using a nontreponemal test followed by testing of reactive sera with a treponemal test. When reverse sequence screening is used, CDC recommends reflexively testing all sera that produce reactive EIA/CIA results with a quantitative nontreponemal test, and reflexively testing sera with discordant results (i.e., reactive EIA/CIA and nonreactive RPR/VDRL test) with a confirmatory Treponema pallidum particle agglutination assay (TP-PA); all test results should be reported promptly and concurrently to the clinician and public health department. Use of treponemal-specific screening tests may increase the rate of donors with screen-reactive, and potentially falsely reactive, results which will exclude donors with past infections. In 2011, the CDC published a landmark study in which syphilis serology results (n = 140,176) from five clinical laboratories using reverse screening between 2006 and 2010 were reviewed. 7 Three of these laboratories served areas with a low incidence of syphilis, while the remaining two labs served a highprevalence population. Among the 140,176 samples screened by EIA or chemiluminescence immunoassays (CLIA), 4,834 (3.4%) were reactive by the treponemal test. Of the 4,834 EIA/CLIA-reactive samples, 2,734 (56.7%) were nonreactive by RPR, of which 866 (31.6%) were also nonreactive by a second treponemal test (e.g., TPPA or FTAABS), suggesting falsely reactive EIA/CLIA results. Interestingly, the percentage of discordant (EIA/CLIA-reactive, RPR nonreactive) serum samples was higher in the lowprevalence population than in the high-prevalence population (60.6 versus 50.6%). It was also observed that the percentage of discordant serum samples testing nonreactive by TPPA or FTA-ABS was greater in the low-prevalence population than in the high prevalence group (40.8% versus 14.4%). In summary, the data indicate that among patients with reactive EIA/CIA results, 56.7% had nonreactive nontreponemal test results and among these discordant sera, 12.2%-60.0% were nonreactive with a second treponemal test. 7 This suggests that reverse screening may identify a higher number of patients with falsely reactive results than the traditional testing algorithm, especially when used in areas with low disease prevalence. We conclude that up to 60% of donors who test positive for the CAPTIA would be disqualified unnecessarily if the new FDA guidelines regarding syphilis screening go into effect as proposed. This would result in an unnecessary reduction of the donor pool of 1.93% due to false positive test results. HCT/P establishments must test a specimen from the donor of cells or tissue, whether viable or nonviable, for evidence of infection due to relevant communicable disease agents, including T. pallidum ( (a)(5)). A tissue donor whose specimen tests positive or reactive on a treponemal screening test is not eligible.

6 Current FDA Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-based Products requires tissue establishments to determine potential donor to be ineligible who have been treated for or had syphilis within the preceding 12 months. Further, this guidance states: We do not recommend deferral of donors if evidence is presented that the treatment occurred more than 12 months ago and was successful. And yet, the testing available would require that those donors are ruled out, even if the treatment was more than 12 months ago. Blood donors may be re-entered into the donor pool if another, different treponemal screening test result is negative or a non-treponemal screening test is nonreactive and the donor provides documentation of successful treatment for syphilis completed at least 2 months before their next blood donation. This is according to the March 2013 Draft Guidance for Industry: Recommendations for Screening, Testing, and Management of Blood Donors and Blood and Blood Components Based on Screening Tests for Syphilis. Cornea donation is a one-time gift and blood samples from an eye donor cannot be re-tested after the time of referral. Parallel studies are needed to determine if the traditional RPR screening test or the treponemaspecific screening test is likely to result in more false-positive results in a donor population with a low prevalence of syphilis. EBAA recently conducted a survey of member eye banks in January 2014 regarding their donor testing for syphilis. Ninety percent (55/61) of U.S. banks who responded are utilizing a diagnostic nontreponemal (RPR) screening test for syphilis, with a confirmatory fluorescent treponemal antibody absorption (FTA-ABS) test. These 55 eye banks represent 77% of the corneal donor pool for U.S. eye banks. The six (6) U.S. banks who reported using an FDA-cleared treponemal donor screening test utilize the CAPTIA TM Syphilis (T. pallidum)-g enzyme immunoassay (EIA). Additionally, four Canadian banks are utilizing the CAPTIA TM Syphilis-G test as part of their donor screening panel. These banks did not report a noticeable increase in donor rule outs and one bank reported that it was more cost effective to do the treponemal test, since there would be fewer false positives and less tissue lost due to time waiting for the confirmatory testing when a non-treponemal test is positive. It should be noted that these six banks are not our larger volume eye banks and only represent 4% of the corneal donor pool. Therefore statistical differences would not be noticed. Since 1962, member banks have provided annual donation and transplantation statistics to EBAA, which reflects the eye banking activity for the previous year. The 2012 Eye Banking Statistical Report is a compilation of information provided to the EBAA by all U.S. member eye banks and reflects an essentially complete picture of eye banking activity in the United States. In 2012, 348 of the 103,774 (0.3%) of the corneas intended for surgery were determined to be ineligible for transplant due to positive syphilis testing. This was using the 2007 Donor Eligibility guidance which allows FDA-cleared diagnostic serological tests for use in donor screening for syphilis. Delaying finalization of this guidance will allow the EBAA, as well as the testing laboratories, to perform these

7 needed studies to determine if treponemal specific screening tests will increase or decrease the number of donors who are ruled out. In February 2013, CDC published two analyses that provide an in-depth look at the severe human and economic burden of sexually transmitted infections (STIs) in the United States. CDC s new estimates were developed using the best available data. The estimates are based on national surveys, nationally notifiable disease case reports, and data from special projects. The primary data source used to estimate the number of most prevalent infections was the National Health and Nutrition Examination Survey (NHANES), a nationally representative sample of the civilian, non-institutionalized population in the United States that includes testing for STIs. The estimated number of new and existing (total) syphilis infections was 117, The proposed syphilis testing guidelines show a lack of coordination of policy implications between organ and tissue donation and transplantation. Approximately 1/3 of organ donors are also tissue donors. 9 If tissue donors must be screened using treponemal-specific screening tests for syphilis and organ donors are not, when a shared donor s EIA test is positive, and that report is received by an organ procurement organization (OPO) or transplant center, the organs may be rejected for transplant. Furthermore, if the organs have already been transplanted, the transplant surgeons may begin unnecessary treatment for syphilis, based on a screening test with a known high false positive rate. These discordant test results do not occur with the traditional testing algorithm because only nontreponemal-reactive sera are tested with a treponemal test. Therefore, we encourage FDA to communicate and coordinate its proposal for testing requirements with HRSA, the Organ Procurement and Transplantation Network (OPTN), and the United Network for Organ Sharing (UNOS). These communication avenues must be pursued, prior to issuing final guidance for HCT/P donor testing, and the FDA and HRSA need to provide guidance on how to treat shared donors with discordant test results. There is no evidence in the literature, either experimental or clinical, to suggest the transmission of syphilis via corneal transplantation. There is no evidence in the literature, either experimental or clinical, to suggest the transmission of syphilis via corneal transplantation. 10 Randolph attempted to establish the experimental transmission of syphilis by transplantation of clear corneas from latently-infected rabbits. 11 Randolph was unable to confirm the transmission of syphilis as manifested by active keratitis or orchitis. Macsai and Norris studied the effects of corneal storage conditions on the survival and infectivity of Treponema pallidum. It was found that T. pallidum became inactivated within 24 hours when incubated in Optisol medium at 4 C under standard corneal storage conditions. 12 There have been no reported cases of syphilis transmission due to corneal transplantation, even before institution of the policy of screening donors for RPR reactivity. In view of this work in animals and the absence of any documented human cases in the literature, it seems unlikely that clear corneas from

8 syphilitic donors are responsible for the transmission of this disease. A possible exception is the eyes of infants with congenital syphilis in whom treponemas have been found in the noninflamed corneas. Ocular syphilis is an unusual manifestation of the disease, typically occurring during the secondary stage. Uveitis is the most common ocular manifestation of syphilis, but may include interstitial keratitis, anterior, intermediate, and posterior uveitis, chorioretinitis, retinitis, retinal vasculitis and cranial nerve and optic neuropathies. Except for the chancre of primary syphilis, which rarely involves the lids or conjunctiva, ocular involvement in syphilis occurs in the secondary stage (usually associated with other systemic findings) or in the late stages. 13 EBAA Medical Standards require that a penlight or portable slit-lamp examination of the anterior segment be performed prior to enucleation or in situ corneoscleral disc excision. Any inflammation (e.g., conjunctivitis, keratitis, scleritis, iritis, uveitis) found would be considered an EBAA contraindication for transplant, and those tissues would not be offered for surgical purposes (EBAA Medical Standards D1.110.A.9.b and E1.100). This provides a further layer of safety. In 1991, the EBAA Medical Standards implemented a policy of mandatory donor syphilis testing for all member eye banks, in the belief that a positive syphilis serology might serve as a surrogate marker for HIV-1 infection. Goldberg et al found a poor correlation between positive syphilis and HIV-1 serology within a donor population as a result of a 1992 screening survey of 8932 donors. 14 Based in part on these results, the requirement for serologic screening for syphilis was eliminated from the EBAA Medical Standards. However, the FDA has determined syphilis to be a relevant communicable disease and disease agent (RCDAD) and requires syphilis testing of all ocular tissue donors. Eye banks are unique among HCT/P establishments, because they perform active surveillance for adverse reactions among the ocular tissue they distribute. Per EBAA Medical Standards, member eye banks are required to request postoperative outcome information between three and six months after transplant from the transplanting surgeon concerning possible adverse reactions on all corneal tissue distributed by the eye bank (EBAA Medical Standard M1.500). Adverse reactions involving the development of systemic infectious disease in a recipient would be reportable to both the EBAA through our Online Adverse Reaction Reporting System (OARRS) and FDA through their MedWatch system. There has never been a reported syphilis infection in the EBAA Online Adverse Reaction Reporting System since its inception in 2004, nor via the paper records prior to that date. The EBAA Medical Advisory Board, which consists of experts in the fields of Ophthalmology and eye banking, regularly reviews the available data on transmission of communicable diseases associated with corneal tissues. OARRS data is presented and reviewed at each semi-annual meeting of the EBAA Medical Advisory Board. When evidence suggests a correlation between a communicable disease and corneal transplant, the Board will recommend listing the condition as a contraindication to donation.

9 Increasing costs are absorbed by the health care system and eye banks. Each additional required test adds to the cost of providing tissue for transplant. As more tests are developed and made available, each test should demonstrate tangible benefit to the screening of donors to justify the increased costs before being added to the list of required tests. Payers are extremely sensitive to cost issues in today s environment. CMS, (the Centers for Medicare and Medicaid Services), under the U.S. Department of Health and Human Services (HHS), is the single largest payer for corneal tissue, and currently reimburses facilities at the eye bank s invoice cost for processing. Additional costs imposed by changes in testing requirements may jeopardize this balance and are particularly counterproductive in the absence of scientific support for increased safety attributable to those changes. Based on the costs of the kits used, the per test reagent costs for the qualitative nontreponemal tests are fairly low ($0.18 to $0.40) in comparison to the treponemal tests, such as the FTA-ABS test ($2.13), the Treponema pallidum particle agglutination (TP-PA) test ($2.14), and the EIA test ($2.33) 6. Most eye/tissue banks do not perform enzyme immunoassays; instead they will need to send clinical specimens to contracted laboratories for syphilis testing. This practice increases the turnaround time and delays corneal transplantation. The traditional approach (RPR screening) has a proven track record and is suitable for HCT/P donors. Finally, the FDA has not thoroughly evaluated the financial implications of implementing this test. These costs include not only the direct costs of the test kits and related implementation, but also the indirect costs to the health care system, including the loss of otherwise eligible donors. The per-test cost for using an EIA screening test for syphilis in place of the diagnostic test is estimated to be an additional $14-$35 per donor. If all donors were tested, the estimated annual testing costs for syphilis would be increased by at least $829,094 ($14 x 59,221 donors). However, the far greater cost to the health care system is the loss of human tissue due to false positive test results. Closing Remarks The EBAA thanks the FDA for the opportunity to comment on the draft guidance document. The Association understands and appreciates the FDA s efforts to help ensure the safety of human tissues for transplant and prevent the transmission of communicable disease by HCT/Ps. We appreciate the opportunity to work with you to ensure the safety of ocular tissue offered for transplant. As was said at the outset, the EBAA has a long and valued history of working with the FDA and our other transplant partners to develop an appropriate regulatory scheme to address emerging infectious agents. These comments are intended to continue that collegial and cooperative spirit. Sincerely, Kevin P. Corcoran, CAE President & CEO

10 References: 1. Pope, V. Medscape: Use of Treponemal Tests to Screen for Syphilis Hooper, N. E., D. C. Malloy, and S. Passen Evaluation of a Treponema pallidum enzyme immunoassay as a screening test for syphilis. Clin. Diagn. Lab. Immunol. 1: Reisner, B. S., L. M. Mann, C. A. Tholcken, R. T. Waite, and G. L. Woods Use of the Treponema pallidum-specific Captia Syphilis IgG assay in conjunction with the rapid plasma reagin to test for syphilis. J. Clin. Microbiol. 35: Loeffelhotz, MJ and Binnicker, MJ. Is It Time To Use Treponema-Specific Antibody Tests for Diagnosis of Syphilis. J Clin Microbiol. 2012; 50(1):2. 5. Binnicker MJ, Jespersen DJ, Rollins LO Direct comparison of the traditional and reverse syphilis screening algorithms in a population with a low prevalence of syphilis. J. Clin. Microbiol. 50: CDC. The Self-Study STD Module Syphilis CDC. Discordant Results from Reverse Sequence Syphilis Screening --- Five Laboratories, United States, MMWR (05); STD Surveillance Syphilis CDC pdf 9. AATB-accredited OPOs: Recovery-Related Survey Report, November Dubord, PJ, Evans, GD, Macsai, MS, et al. Eye Banking and Corneal Transplantation Communicable Adverse Incidents: Current Status and Project NOTIFY. Cornea. 2013;32: Randolph ME. An experimental study of the possibility of transmitting syphilis by a corneal graft. Trans Am Ophthalmol Soc. 1949;47: Macsai, MS and Norris, SJ. OptiSol Corneal Storage Medium and Transmission of Treponema Pallidum. Cornea. 1995;14(6): Kiss S, Damico FM, Young LH. Ocular manifestations and treatment of syphilis. Semin Ophthalmol Jul-Sep;20(3): Goldberg, MA, Laycock, KA,Kinard S, et al. Poor correlation between reactive syphilis serology and human immunodeficiency virus testing among potential cornea donors. Am J Ophthalmol. 1995;119:1-6.

Guidance for Industry

Guidance for Industry Guidance for Industry Revised Recommendations for Donor and Product Management Based on Screening Tests for Syphilis DRAFT GUIDANCE This document is being distributed for comment purposes only. Submit

More information

Use of Treponemal Immunoassays for Screening and Diagnosis of Syphilis

Use of Treponemal Immunoassays for Screening and Diagnosis of Syphilis Use of Treponemal Immunoassays for Screening and Diagnosis of Syphilis Guidance for Medical Providers and Laboratories in California These guidelines were developed by the California Department of Public

More information

Direct Comparison of the Traditional and Reverse Syphilis Screening Algorithms

Direct Comparison of the Traditional and Reverse Syphilis Screening Algorithms JCM Accepts, published online ahead of print on 16 November 2011 J. Clin. Microbiol. doi:10.1128/jcm.05636-11 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions. All

More information

Susanne Norris Zanto, MPH, MLS (ASCP) CM, SM Montana Public Health Laboratory

Susanne Norris Zanto, MPH, MLS (ASCP) CM, SM Montana Public Health Laboratory Susanne Norris Zanto, MPH, MLS (ASCP) CM, SM Montana Public Health Laboratory Describe the challenges in syphilis diagnostics Present two testing algorithms Non-treponemal test as initial screen Treponemal

More information

10/19/2012. Serologic Testing for Syphilis. Disclosures. Comparison of the Traditional and Reverse Screening Algorithms. Outline.

10/19/2012. Serologic Testing for Syphilis. Disclosures. Comparison of the Traditional and Reverse Screening Algorithms. Outline. Serologic Testing for Syphilis Comparison of the Traditional and Reverse Screening Algorithms Disclosures Elli S. Theel, Ph.D. Director, Infectious Diseases Serology Laboratory Assistant Professor of Laboratory

More information

Serological screening for syphilis in HIV-infected individuals: is a non-treponemal test adequate in the era of increasing of new syphilis infections?

Serological screening for syphilis in HIV-infected individuals: is a non-treponemal test adequate in the era of increasing of new syphilis infections? Abstract no. WEPE 494 Serological screening for syphilis in HIV-infected individuals: is a non-treponemal test adequate in the era of increasing of new syphilis infections? G.Chrysos 1, D.Karageorgopoulos

More information

Guidance for Industry

Guidance for Industry Reprinted from FDA s website by Guidance for Industry Recommendations for Screening, Testing, and Management of Blood Donors and Blood and Blood Components Based on Screening Tests for Syphilis DRAFT GUIDANCE

More information

Replaces: 04/13/17. / Formulated: 7/05 SYPHLIS

Replaces: 04/13/17. / Formulated: 7/05 SYPHLIS Effective Date: 81017 Replaces: 041317 Page 1 of 7 POLICY: The Texas Department of Criminal Justice (TDCJ) will identify, test, and manage all offenders with suspected or confirmed syphilis with a uniform

More information

SYPHILIS (Treponema pallidum) IMMEDIATE NOTIFICATION STD PROGRAM

SYPHILIS (Treponema pallidum) IMMEDIATE NOTIFICATION STD PROGRAM SYPHILIS (Treponema pallidum) IMMEDIATE NOTIFICATION STD PROGRAM Event Name: Event Time Period: Clinical Description (CDC 2014) Syphilis 180 days Syphilis is a complex sexually transmitted disease that

More information

4/18/2018. Syphilis Testing. Disclosure. Learner Objectives. Outline. Employee and stockholder of Bio-Rad Laboratories, Inc.

4/18/2018. Syphilis Testing. Disclosure. Learner Objectives. Outline. Employee and stockholder of Bio-Rad Laboratories, Inc. Disclosure Employee and stockholder of Bio-Rad Laboratories, Inc. Unraveling the Complexities of Syphilis Testing Maria Crisostomo, April 30 & May 1, 2018 2 Learner Objectives Syphilis Testing Upon completion

More information

December 20, Dear Dr. Frieden:

December 20, Dear Dr. Frieden: December 20, 2011 The Honorable Thomas Frieden, MD, MPH Director, Centers for Disease Control and Prevention 1600 Clifton Road, NE. Mailstop A-07 Atlanta, GA 30329 Ref: [Docket No. CDC-2011-0011]; Public

More information

Syphilis Treatment Protocol

Syphilis Treatment Protocol STD, HIV, AND TB SECTION Syphilis Treatment Protocol CLINICAL GUIDANCE FOR PRIMARY AND SECONDARY SYPHILIS AND LATENT SYPHILIS www.lekarzol.com (4/2016) Page 1 of 8 Table of Contents Description... 3 Stages

More information

Guidance for Industry

Guidance for Industry Reprinted from FDA s website by EAS Consulting Group, LLC Guidance for Industry Recommendations for Screening, Testing, and Management of Blood Donors and Blood and Blood Components Based on Screening

More information

Report on the Transplantation Transmission Sentinel Network (TTSN)

Report on the Transplantation Transmission Sentinel Network (TTSN) Report on the Transplantation Transmission Sentinel Network (TTSN) CATB Session - AATB s 31st Annual Meeting, Boston September 15, 2007 Scott Brubaker, CTBS AATB Representative, TTSN Advisory Group TTSN

More information

Sexually Transmitted Diseases Treatment Guidelines, 2015

Sexually Transmitted Diseases Treatment Guidelines, 2015 Morbidity and Mortality Weekly Report Recommendations and Reports / Vol. 64 / No. 3 June 5, 2015 Sexually Transmitted Diseases Treatment Guidelines, 2015 U.S. Department of Health and Human Services Centers

More information

Syphilis Update: New Presentations of an Old Disease

Syphilis Update: New Presentations of an Old Disease Syphilis Update: New Presentations of an Old Disease Bradley Stoner, MD, PhD Washington University in St. Louis Disclosure: Bradley Stoner, MD, PhD STDs in the United States Where do we stand right now?

More information

Performance Characteristics of the Reverse Syphilis Screening Algorithm in a Population With a Moderately High Prevalence of Syphilis

Performance Characteristics of the Reverse Syphilis Screening Algorithm in a Population With a Moderately High Prevalence of Syphilis Performance Characteristics of the Reverse Syphilis Screening Algorithm in a Population With a Moderately High Prevalence of Syphilis Angela R. Rourk, Frederick S. Nolte, PhD, and Christine M. Litwin,

More information

The Use of a Rapid Syphilis Test with Specimens from an HIV Cluster Investigation in Rural West Virginia

The Use of a Rapid Syphilis Test with Specimens from an HIV Cluster Investigation in Rural West Virginia National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention The Use of a Rapid Syphilis Test with Specimens from an HIV Cluster Investigation in Rural West Virginia Lara E. Pereira, Ph.D. Centers

More information

Syphilis Technical Instructions for Civil Surgeons

Syphilis Technical Instructions for Civil Surgeons National Center for Emerging and Zoonotic Infectious Diseases Syphilis Technical Instructions for Civil Surgeons Joanna J. Regan, MD, MPH, FAAP Medical Officer Medical Assessment and Policy Team Immigrant,

More information

Validation of a New Testing Algorithm for Syphilis in Trinidad & Tobago

Validation of a New Testing Algorithm for Syphilis in Trinidad & Tobago Validation of a New Testing Algorithm for Syphilis in Trinidad & Tobago R. Dass, A. Sebro, J. Edwards Ministry of Health, Trinidad and Tobago rianna.dass@hotmail.com, asebro@yahoo.com, jeffreye2000@gmail.com

More information

Evaluation of the LIAISON Treponema Assay, a Chemiluminescent Immunoassay ACCEPTED

Evaluation of the LIAISON Treponema Assay, a Chemiluminescent Immunoassay ACCEPTED CVI Accepts, published online ahead of print on 25 April 2007 Clin. Vaccine Immunol. doi:10.1128/cvi.00068-07 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All

More information

CAP Laboratory Improvement Programs. Prevalence of Traditional and Reverse-Algorithm Syphilis Screening in Laboratory Practice

CAP Laboratory Improvement Programs. Prevalence of Traditional and Reverse-Algorithm Syphilis Screening in Laboratory Practice CAP Laboratory Improvement Programs Prevalence of Traditional and Reverse-Algorithm Syphilis Screening in Laboratory Practice A Survey of Participants in the College of American Pathologists Syphilis Serology

More information

2/13/ Graphic photographs or cartoons used during this presentation might be offensive to some; for this I apologize in advance.

2/13/ Graphic photographs or cartoons used during this presentation might be offensive to some; for this I apologize in advance. Leon Bullard, MD, MA Medical Consultant, DHEC, DADE The 23 rd Annual APRN Conference Charleston, SC February 24, 2017 1. Provide a brief (very) review of the syphilis story. 2. Define and discuss the stages

More information

[Submitted Electronically]

[Submitted Electronically] [Submitted Electronically] Dr. Matthew J. Kuehnert, Director Office of Blood, Organ, and Other Tissue Safety Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic Infectious

More information

Public/Private Partnerships: Intervening in the Spread of Syphilis

Public/Private Partnerships: Intervening in the Spread of Syphilis Public/Private Partnerships: Intervening in the Spread of Diana Torres-Burgos MD, MPH Gerard Castaneda, BSN Alana Thomas, BS STD/HIV Update Conference Grand Rapids, MI 3/11/2014 Outline overview Stages

More information

Sex, Sores, Science, and Surveillance: Syphilis in the 21 st Century (U046)

Sex, Sores, Science, and Surveillance: Syphilis in the 21 st Century (U046) Sex, Sores, Science, and Surveillance: Syphilis in the 21 st Century (U046) Kenneth A. Katz, MD, MSc, MSCE Dermatologist, Kaiser Permanente, San Francisco, CA AAD Annual Meeting, Orlando, FL March 4, 2017

More information

The TTSN - A Collaborative Biovigilance System

The TTSN - A Collaborative Biovigilance System The TTSN - A Collaborative Biovigilance System 5th World Congress on Tissue Banking 12th International Conference of the APASTB Kuala Lumpur, Malaysia June 4, 2008 Scott A. Brubaker, CTBS American Association

More information

Treponema-Specific Tests for Serodiagnosis of Syphilis: Comparative Evaluation of Seven Assays

Treponema-Specific Tests for Serodiagnosis of Syphilis: Comparative Evaluation of Seven Assays JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 2011, p. 1313 1317 Vol. 49, No. 4 0095-1137/11/$12.00 doi:10.1128/jcm.02555-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Treponema-Specific

More information

Clinical Application of New Treponemal Antibody Test in Blood Donors

Clinical Application of New Treponemal Antibody Test in Blood Donors Clinical Application of New Treponemal Antibody Test in Blood Donors Parichart Permpikul, MD Department of Transfusion Medicine Faculty of Medicine Siriraj Hospital Mahidol University Bangkok, Thailand

More information

Int.J.Curr.Microbiol.App.Sci (2018) 7(8):

Int.J.Curr.Microbiol.App.Sci (2018) 7(8): International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 7 Number 08 (2018) Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2018.708.085

More information

Sex, Sores, Science, and Surveillance: Syphilis in the 21 st Century (U046)

Sex, Sores, Science, and Surveillance: Syphilis in the 21 st Century (U046) Sex, Sores, Science, and Surveillance: Syphilis in the 21 st Century (U046) Kenneth A. Katz, MD, MSc, MSCE Dermatologist, Kaiser Permanente, San Francisco, CA AAD Annual Meeting, San Diego, CA February

More information

23 November Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

23 November Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852 23 November 2016 Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Submitted via http://www.regulations.gov Re: Docket No. FDA-2016-N-1502,

More information

Syphilis Testing in Northern California Kaiser

Syphilis Testing in Northern California Kaiser Syphilis Testing in Northern California Kaiser Jen Shieh, MS, CLS Test Development Scientist Kaiser Permanente TPMG Regional Laboratory Microbiology Department Kaiser Permanente 3.3 million members 22

More information

2009 Eye Banking Statistical Report Eye Bank Association of America th Street, N.W. Suite 1010 Washington, DC Phone (202) Fax

2009 Eye Banking Statistical Report Eye Bank Association of America th Street, N.W. Suite 1010 Washington, DC Phone (202) Fax 2009 Eye Banking Statistical Report Eye Bank Association of America 1015 18th Street, N.W. Suite 1010 Washington, DC 20036 Phone (202) 775-4999 Fax (202) 429-6036 www.restoresight.org Introduction 2009

More information

Comparison of Automated Treponemal and Nontreponemal Test Algorithms as First-Line Syphilis Screening Assays

Comparison of Automated Treponemal and Nontreponemal Test Algorithms as First-Line Syphilis Screening Assays Original Article Diagnostic Immunology Ann Lab Med 2016;36:23-27 http://dx.doi.org/10.3343/alm.2016.36.1.23 ISSN 2234-3806 eissn 2234-3814 Comparison of Automated Treponemal and Nontreponemal Test Algorithms

More information

Antibodies to Treponema pallidum

Antibodies to Treponema pallidum APPLIED MICROBIOLOGY, July 1972, p. 26- Copyright 0 1972 American Society for Microbiology Vol. 24, No. 1 Printed in U.S.A. Evaluation of the Qualitative and Automated Quantitative Microhemagglutination

More information

9/9/2015. Began to see a shift in 2012 Early syphilis cases more than doubled from year before

9/9/2015. Began to see a shift in 2012 Early syphilis cases more than doubled from year before George Walton, MPH, CPH, MLS(ASCP) CM STD Program Manager Bureau of HIV, STD, and Hepatitis September 15, 2015 1 1) Discuss the changing epidemiology of syphilis in Iowa; 2) Explore key populations affected

More information

Revisions to the Syphilis Surveillance Case Definitions, 2018

Revisions to the Syphilis Surveillance Case Definitions, 2018 National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Revisions to the Syphilis Surveillance Case Definitions, 2018 Sarah Kidd, MD, MPH Medical Epidemiologist Division of STD Prevention

More information

VDRL v/s TPHA for diagnosis of syphilis among HIV sero-reactive patients in a tertiary care hospital

VDRL v/s TPHA for diagnosis of syphilis among HIV sero-reactive patients in a tertiary care hospital ISSN: 2319-7706 Volume 3 Number 5 (2014) pp. 726-730 http://www.ijcmas.com Original Research Article VDRL v/s TPHA for diagnosis of syphilis among HIV sero-reactive patients in a tertiary care hospital

More information

Documentation, Codebook, and Frequencies

Documentation, Codebook, and Frequencies Documentation, Codebook, and Frequencies MEC Laboratory Component: Syphilis(IgG), Syphilis Rapid Plasma Reagin (RPR), and Treponema pallidum Particle Agglutination (TP- PA) Survey Years: 2003 to 2004 SAS

More information

Didactic Series. STD Screening & Management: Syphilis. Christian B. Ramers, MD, MPH

Didactic Series. STD Screening & Management: Syphilis. Christian B. Ramers, MD, MPH Didactic Series STD Screening & Management: Syphilis Christian B. Ramers, MD, MPH Assistant Medical Director Family Health Centers of San Diego Ciaccio Memorial Clinic 3/26/15 ACCREDITATION STATEMENT:

More information

Lisa Villarroel, MD MPH Medical Director, Division of Public Health Preparedness Arizona Department of Health Services.

Lisa Villarroel, MD MPH Medical Director, Division of Public Health Preparedness Arizona Department of Health Services. Lisa Villarroel, MD MPH Medical Director, Division of Public Health Preparedness Arizona Department of Health Services Disclosures: None 1 PRIMARY Fitzgerald TJ, Cleveland P, Johnson RC et al: Scanning

More information

Clinical Education Initiative TITLE: UPDATE ON MSM SEXUAL HEALTH. Speaker: Maureen Scahill, MS NP

Clinical Education Initiative TITLE: UPDATE ON MSM SEXUAL HEALTH. Speaker: Maureen Scahill, MS NP Clinical Education Initiative Support@ceitraining.org TITLE: UPDATE ON MSM SEXUAL HEALTH Speaker: Maureen Scahill, MS NP 1/25/2017 2/10/2017 Update on MSM Sexual Health [video transcript] 00:00:08 - [Maureen]

More information

Treponemal-Specific Tests for the Serodiagnosis of Syphilis: A Comparative Evaluation of Seven Assays

Treponemal-Specific Tests for the Serodiagnosis of Syphilis: A Comparative Evaluation of Seven Assays JCM Accepts, published online ahead of print on 23 February 2011 J. Clin. Microbiol. doi:10.1128/jcm.02555-10 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions. All

More information

Nothing to disclose.

Nothing to disclose. Update on Diagnosis and Treatment Lisa Winston, MD University of California, San Francisco/ Zuckerberg San Francisco General Nothing to disclose. 1 This talk will be a little depressing Rising incidence

More information

Interpreting Syphilis Serology

Interpreting Syphilis Serology Interpreting Syphilis Serology Dr Beng Goh Royal London Hospital Barts & The London NHS Trust beng.goh@bartsandthelondon.nhs.uk Serological Tests for Syphilis: Principles Screening Confirmation Staging

More information

Background. Restricted Siemens Healthcare GmbH, >1 year Late latent syphilis. Restricted Siemens Healthcare GmbH, 2017

Background. Restricted Siemens Healthcare GmbH, >1 year Late latent syphilis. Restricted Siemens Healthcare GmbH, 2017 Background Nonneutralizing The Evolution of Syphilis Testing: Clinical Benefits of a Reverse Screening Algorithm Katherine Soreng PhD Lafond RE, et al. Clin Microbiol Rev. 06;19(1):29 49. Disease course:

More information

June 8, Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

June 8, Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852 June 8, 2018 Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Submitted via http://www.regulations.gov Re: Docket No. FDA 2016 D 0545,

More information

May 16, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852

May 16, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 701 Pennsylvania Avenue, NW Suite 800 Washington, D.C. 20004 2654 Tel: 202 783 8700 Fax: 202 783 8750 www.advamed.org May 16, 2014 Division of Dockets Management (HFA-305) Food and Drug Administration

More information

test. It appeared that the MHA-TP test could be

test. It appeared that the MHA-TP test could be JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 1983, p. 405-409 0095-1137/83/030405-05$02.00/0 Copyright 1983, American Society for Microbiology Vol. 17, No. 3 Reactivity of Microhemagglutination, Fluorescent

More information

Identifying false-positive syphilis antibody results using a semi-quantitative

Identifying false-positive syphilis antibody results using a semi-quantitative CVI Accepts, published online ahead of print on 20 April 2011 Clin. Vaccine Immunol. doi:10.1128/cvi.05066-11 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions. All

More information

Case 1. FDA, Legal, and EBAA Medical Standards Panel. Case 1. Case 1 6/25/2012. Samuel B. Barone, M.D. Office of Cellular, Tissue, and Gene Therapies

Case 1. FDA, Legal, and EBAA Medical Standards Panel. Case 1. Case 1 6/25/2012. Samuel B. Barone, M.D. Office of Cellular, Tissue, and Gene Therapies Case 1 FDA, Legal, and EBAA Medical Standards Panel Samuel B. Barone, M.D. Office of Cellular, Tissue, and Gene Therapies Medical Directors Symposium Eye Bank Association of America Annual Meeting 47 y/o

More information

Analysis of 3 Algorithms for Syphilis Serodiagnosis and Implications for Clinical Management

Analysis of 3 Algorithms for Syphilis Serodiagnosis and Implications for Clinical Management MAJOR ARTICLE Analysis of 3 Algorithms for Syphilis Serodiagnosis and Implications for Clinical Management Man-Li Tong, 1,a Li-Rong Lin, 1,2,a Li-Li Liu, 1,2,3,a Hui-Lin Zhang, 1 Song-Jie Huang, 1 Yu-Yan

More information

Fact Sheet for Health Care Providers: Interpreting Results from the Aptima Zika Virus assay. September 7, 2016

Fact Sheet for Health Care Providers: Interpreting Results from the Aptima Zika Virus assay. September 7, 2016 Dear Health Care Provider: Fact Sheet for Health Care Providers: Interpreting Results from the Aptima Zika Virus assay September 7, 2016 The U.S. Food and Drug Administration (FDA) has issued an Emergency

More information

Evaluation of a New Rapid Plasma Reagin Card Test as a Screening Test for Syphilis

Evaluation of a New Rapid Plasma Reagin Card Test as a Screening Test for Syphilis JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 1982, p. 286-290 0095-1 137/82/080286-05$02.00/0 Vol. 16, No. 2 Evaluation of a New Rapid Plasma Reagin Card Test as a Screening Test for Syphilis MARY W. PERRYMAN,'*

More information

Syphilis. syphilis. Sera from all stages of syphilis and the. to compare dilution titers with those obtained

Syphilis. syphilis. Sera from all stages of syphilis and the. to compare dilution titers with those obtained JOURNAL OF CLINICAL MICROBIOLOGY, Feb. 1982, p. 238-242 0095-1137/82/020238-05$02.00/0 Vol. 15, No. 2 Unheated Serum Reagin Test as a Quantitative Test for Syphilis DEBORAH E. PETTIT, SANDRA A. LARSEN,*

More information

Treponema Pallidum Total Antibody ELISA

Treponema Pallidum Total Antibody ELISA For Research Use Only. Not for use in Diagnostic Procedures. INTENDED USE The GenWay, Inc. Treponima pallidum Total ELISA Kit is intended for the detection of IgG, IgM and IgA antibody to Treponima pallidum

More information

Analytical Comparison of the Architect Syphilis TP and Liaison Treponema Assay

Analytical Comparison of the Architect Syphilis TP and Liaison Treponema Assay JCM Accepted Manuscript Posted Online 16 May 2018 J. Clin. Microbiol. doi:10.1128/jcm.00215-18 Copyright 2018 American Society for Microbiology. All Rights Reserved. 1 2 3 Analytical Comparison of the

More information

Discordant Results from Reverse Sequence Syphilis Screening Five Laboratories, United States,

Discordant Results from Reverse Sequence Syphilis Screening Five Laboratories, United States, Please note: An erratum has been published for this issue. To view the erratum, please click here. Morbidity and Mortality Weekly Report Weekly / Vol. 60 / No. 5 February 11, 2011 Discordant Results from

More information

2006 HIV Diagnostics Survey

2006 HIV Diagnostics Survey Public Health Laboratory Issues in Brief: 2006 HIV Diagnostics Survey Association of Public Health Laboratories November 2007 Background Nearly 20 years ago, the Association of Public Health Laboratories

More information

Gonorrhea, Chlamydia, and Syphilis in Alaska

Gonorrhea, Chlamydia, and Syphilis in Alaska Department of Health and Social Services Division of Public Health Section of Epidemiology Karen Perdue, Commissioner Karen Pearson, Director John Middaugh, MD, Editor 361 C Street, Suite 54, P.O. Box

More information

Screening for Syphilis Updated Evidence Report and Systematic Review for the US Preventive Services Task Force

Screening for Syphilis Updated Evidence Report and Systematic Review for the US Preventive Services Task Force Clinical Review & Education US Preventive Services Task Force EVIDENCE REPORT Screening for Syphilis Updated Evidence Report and Systematic Review for the US Preventive Services Task Force Amy G. Cantor,

More information

5/1/2017. Sexually Transmitted Diseases Burning Questions

5/1/2017. Sexually Transmitted Diseases Burning Questions Sexually Transmitted Diseases Burning Questions Jeffrey D. Klausner, MD, MPH Professor of Medicine and Public Health University of California Los Angeles Los Angeles, California FORMATTED: 04-03-17 Financial

More information

TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES ADVISORY COMMITTEE MEETING October2010. Issue Summary

TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES ADVISORY COMMITTEE MEETING October2010. Issue Summary TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES ADVISORY COMMITTEE MEETING 28-29October2010 Issue Summary Informational Topic: FDA s Geographic Donor Deferral Policy to Reduce the Possible Risk of Transmission

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Adequate and Appropriate Donor Screening Tests for Hepatitis B; Hepatitis B Surface Antigen (HBsAg) Assays Used to Test Donors of Whole Blood and Blood Components, Including Source

More information

Syphilis among MSM: Clinical Care and Public Health Reporting

Syphilis among MSM: Clinical Care and Public Health Reporting Massachusetts Department of Public Health Bureau of Infectious Disease and Laboratory Sciences Syphilis among MSM: Clinical Care and Public Health Reporting Kevin Ard, MD, MPH, Medical Director, National

More information

2015-Activities, Tissue Types and Inspections

2015-Activities, Tissue Types and Inspections 2015-Activities, Tissue Types and Inspections Form Approved OMB No. 0990-0457 Exp. Date 06/30/2020 Welcome to the 2015 Activities Tissue Types and Inspections survey. Please refer to the following instructions

More information

Case 1. Case 1. Physical exam

Case 1. Case 1. Physical exam 11/13/2012 Case 28 year-old woman Complains of very painful lesions in vulvar area Increasing severity since 4 days Pain aggravated by urination She has a slight fever and also complains of headache and

More information

Screening Donated Blood for Transfusion Transmissible Infections in Bangladesh

Screening Donated Blood for Transfusion Transmissible Infections in Bangladesh Screening Donated Blood for Transfusion Transmissible Infections in Bangladesh National Guidelines 2013 Foreword Mandatory screening of donated blood for transfusion in Bangladesh began in 2000 after implementation

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Advisement for the Use of Gen-Probe Procleix Ultrio Plus Assay for NAT Testing on Cadaveric Donors Release Date: 08/03/14 American Medical Education and Research Association 4757

More information

G-B 2016 Kit Instructions CAP 2016

G-B 2016 Kit Instructions CAP 2016 G-B 2016 Kit Instructions CAP 2016 Syphilis Serology Survey Table of Contents Kit Contents Kit Contents... 1 Important: Before You Begin... 1 Detailed Testing Instructions... 1 Reporting Your Results...

More information

Evaluation of a Treponema pallidum Enzyme Immunoassay as a Screening Test for Syphilis

Evaluation of a Treponema pallidum Enzyme Immunoassay as a Screening Test for Syphilis CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, JUly 1994, p. 477-481 Vol. 1, No. 4 1071-412X/94/$04.00+0 Copyright C 1994, American Society for Microbiology Evaluation of a Treponema pallidum Enzyme Immunoassay

More information

2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies

2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies 2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies Submitted by: Malaysia Policy Dialogue and Workshop on Attaining a Safe and Sustainable Blood Supply Chain Manila, Philippines 30 September 1

More information

WHAT DO U KNOW ABOUT STIS?

WHAT DO U KNOW ABOUT STIS? WHAT DO U KNOW ABOUT STIS? Rattiya Techakajornkeart MD. Bangrak STIs Cluster, Bureau of AIDS, TB and STIs, Department of Disease Control, MOPH, Thailand SEXUALLY TRANSMITTED INFECTIONS? STIs Infections

More information

January Dear Physician:

January Dear Physician: Richard F. Daines, M.D. Commissioner Wendy E. Saunders Executive Deputy Commissioner January 2009 Dear Physician: The purpose of this letter is to bring your attention to the significant increase in reported

More information

Syphilis. sera from the Venereal Disease Serology Laboratory. Serum Bank, Centers for Disease Control, Atlanta,

Syphilis. sera from the Venereal Disease Serology Laboratory. Serum Bank, Centers for Disease Control, Atlanta, JOURNAL OF CLINICAL MICROBIOLOGY, Oct. 1981, p. 441-445 0095-1137/81/0441-05$02.00/0 Vol. 14, No. 4 Specificity, Sensitivity, and Reproducibility Among the Fluorescent Treponemal Antibody-Absorption Test,

More information

SYPHILIS. The Great Pretender K. Amen Eguakun, MSN, APRN, AAHIVS

SYPHILIS. The Great Pretender K. Amen Eguakun, MSN, APRN, AAHIVS SYPHILIS The Great Pretender K. Amen Eguakun, MSN, APRN, AAHIVS Learning Objectives At the end of this presentation, the participants will be able to 1. Describe the epidemiology of syphilis in the United

More information

INFECTIOUS SYPHILIS NOTIFICATION FORM

INFECTIOUS SYPHILIS NOTIFICATION FORM INFECTIOUS SYPHILIS NOTIFICATION FORM This is a Schedule 1, Section C disease notifiable to the Medical Officer of Health under Sections 74 and 74AA of the Health Act 1956 using non-identifiable data.

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Lookback for Hepatitis C Virus (HCV): Product Quarantine, Consignee Notification, Further Testing, Product Disposition, and Notification of Transfusion Recipients Based on Donor Test

More information

Learning Objectives. Syphilis. Lessons. Epidemiology: Disease in the U.S. Syphilis Definition. Transmission. Treponema pallidum

Learning Objectives. Syphilis. Lessons. Epidemiology: Disease in the U.S. Syphilis Definition. Transmission. Treponema pallidum Learning Objectives Syphilis Treponema pallidum 1 Upon completion of this content, the learner will be able to 1. Describe the epidemiology of syphilis in the U.S. 2. Describe the pathogenesis of T. pallidum.

More information

July 14, Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

July 14, Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852 July 14, 2015 Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Submitted via http://www.regulations.gov Re: Docket No. FDA-2015-D-1211

More information

The Great Imitator Revealed: Syphilis

The Great Imitator Revealed: Syphilis The Great Imitator Revealed: Syphilis Jeffrey D. Klausner, MD, MPH Professor of Medicine and Public Health University of California Los Angeles David Geffen School of Medicine Los Angeles, California Learning

More information

Evaluation of a Fully Automated Treponemal Test and Comparison With Conventional VDRL and FTA-ABS Tests

Evaluation of a Fully Automated Treponemal Test and Comparison With Conventional VDRL and FTA-ABS Tests Immunopathology / Evaluation of an Automated Treponemal Test Evaluation of a Fully Automated Treponemal Test and Comparison With Conventional VDRL and FTA-ABS Tests Yongjung Park, MD, 1 Younhee Park, MD,

More information

Clinical Practice Guideline

Clinical Practice Guideline 1 of 10 1.0 Purpose 1.1 To improve and focus efforts to respond to clusters and outbreaks of infectious syphilis and reduce transmission in the Winnipeg Health Region by enhancing treatment options for

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Use of Nucleic Acid Tests on Pooled and Individual Samples from Donors of Whole Blood and Blood Components (including Source Plasma and Source Leukocytes) to Adequately and Appropriately

More information

SYPHILIS HEALTH CHECK

SYPHILIS HEALTH CHECK SYPHILIS HEALTH CHECK Rev. P, 02/17 CLIA Complexity: WAIVED for Fingerstick Whole Blood Specimens ONLY For in vitro diagnostic use only Rx Only A Certificate of Waiver is required to perform this test

More information

To view an archived recording of this presentation please click the following link:

To view an archived recording of this presentation please click the following link: To view an archived recording of this presentation please click the following link: http://pho.adobeconnect.com/p16lj8z0qm3/ Please scroll down this file to view a copy of the slides from the session.

More information

Treponema pallidum Total ELISA Kit

Treponema pallidum Total ELISA Kit Treponema pallidum Total ELISA Kit Catalog Number KA0970 96 assays Version: 03 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Intended Use... 3 Background... 3 Principle

More information

Syphilis in the 21 st Century: Sex, Sores, Science, and Surveillance. Syphilis in Men

Syphilis in the 21 st Century: Sex, Sores, Science, and Surveillance. Syphilis in Men Syphilis in the 21 st Century: Sex, Sores, Science, and Surveillance Syphilis in Men Kenneth A. Katz, MD, MSc, MSCE Kaiser Permanente, San Francisco, CA AAD Annual Meeting Washington, D.C. March 2, 2019

More information

Clinical Practice Guideline with Delegation of Function

Clinical Practice Guideline with Delegation of Function 1 of 8 1.0 Purpose 1.1 To improve and focus efforts to treat those at risk for undiagnosed/untreated incubating, primary, secondary, or early latent infectious syphilis. 2.0 Scope and Goal 2.1 Antibiotic

More information

Annals of Internal Medicine. 1991;114:

Annals of Internal Medicine. 1991;114: Serologic Response to Treatment of Infectious Syphilis Barbara Romanowski, MD; Ruth Sutherland, DPH, RN; Gordon H. Fick, PhD; Debbie Mooney, BSc; and Edgar J. Love, MD, PhD Objective: To evaluate the serologic

More information

Evaluation of the Bio-EnzaBead Test for Syphilis

Evaluation of the Bio-EnzaBead Test for Syphilis JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 1987, p. 619-623 0095-1137/87/040619-05$02.00/0 Copyright 1987, American Society for Microbiology Vol. 25, No. 4 Evaluation of the Bio-EnzaBead Test for Syphilis

More information

Maximizing Cornea and Tissue Donation through Specimen Quality

Maximizing Cornea and Tissue Donation through Specimen Quality Maximizing Cornea and Tissue Donation through Specimen Quality Robert W. Bresler, Sydney D. Gastreich, Elias G. Koulouriotis, Linda S. Martin, Susan Diane Brockmeier, Chak-Sum Ho, PhD Abstract Purpose:

More information

UDHQ Project Overview and Update 7 May 2012

UDHQ Project Overview and Update 7 May 2012 Introduction Organ, tissue, and eye (OTE) donation and transplantation professionals have long understood the value of collecting medical and behavioral history information on potential donors to assess

More information

Guidelines for the Laboratory Detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Treponema pallidum Testing

Guidelines for the Laboratory Detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Treponema pallidum Testing Guidelines for the Laboratory Detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Treponema pallidum Testing Recommendations from the an expert consultation meeting held at CDC January 13-15,

More information

BMJ Open. Comparison of the automated rapid plasma reagin (RPR) test versus the conventional RPR card test in syphilis testing

BMJ Open. Comparison of the automated rapid plasma reagin (RPR) test versus the conventional RPR card test in syphilis testing Comparison of the automated rapid plasma reagin (RPR) test versus the conventional RPR card test in syphilis testing Journal: BMJ Open Manuscript ID: bmjopen-0-00 Article Type: Research Date Submitted

More information

Results of the 2014 Survey

Results of the 2014 Survey Syphilis Testing Practices in the Region of the Americas: 1 Syphilis Testing Practices in the Americas Region: Washington, D.C. 2016 Prepared by: Thuy Trinh¹, Mary L Kamb¹, Minh Luu², D. Cal Ham¹, Freddy

More information

HIV SCREENING WORKSHOP Exercise

HIV SCREENING WORKSHOP Exercise HIV SCREENING WORKSHOP Exercise INTRODUCTION: Since its first discovery in 1981, AIDS became a pandemic. Worldwide, actually over 30 million people are living with HIV (i.e., are infected by the human

More information

Evaluation of Reagin Screen, a New Serological Test for Syphilis

Evaluation of Reagin Screen, a New Serological Test for Syphilis JOURNAL OF CUNICAL MICROBIOLoGY, Aug. 1976, p. 145-150 Copyright 1976 American Society for Microbiology Vol. 4, No. 2 Printed in U.S.A. Evaluation of Reagin Screen, a New Serological Test for Syphilis

More information

Management of Syphilis in Patients with HIV

Management of Syphilis in Patients with HIV Management of Syphilis in Patients with HIV Adult Clinical Guideline from the New York State Department of Health AIDS Institute www.hivguidelines.org Purpose of the Guideline Increase the numbers of NYS

More information